Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.64 |
| ▸ | TP53 | P04637 | 1/20 | 0.64 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.56 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 4/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | F2 | P00734 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | SCN1A | P35498 | 1/20 | 0.50 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.50 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15253339 | 1.00 | TSHR (0.64) | TSHRTP53PDCD1CD274LMNA | |
| SCHEMBL15253524 | 1.00 | TSHR (0.64) | TSHRTP53PDCD1CD274LMNA | |
| SCHEMBL28525420 | 0.98 | TSHR (0.62) | TSHRTP53PDCD1CD274LMNA | |
| Cadaverine Tartrate SCHEMBL3838009 | 0.93 | TSHR (0.56) | TSHRTP53PDCD1CD274LMNA | |
| SCHEMBL14297427 | 0.86 | NPC1 (0.61) | TSHRTP53PDCD1CD274LMNA | |
| SCHEMBL8128097 | 0.86 | TSHR (0.57) | TSHRTP53PDCD1CD274LMNA | |
| SCHEMBL11275122 | 0.86 | CA1 (0.50) | TSHRTP53PDCD1CD274LMNA | |
| SCHEMBL14570072 | 0.84 | TDP1 (0.53) | TSHRTP53PDCD1CD274LMNA | |
| SCHEMBL5835673 | 0.84 | CA12 (0.69) | TSHRTP53PDCD1CD274LMNA | |
| SCHEMBL3899178 | 0.84 | KMT2A (0.55) | TSHRTP53PDCD1CD274LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1886677-A1 | Use of an inducing agent for the treatment of blood, viral and cellular disorders | Perrine, Susan P. (US) | 2008-02-13 | — | — | EP | claimed |
| EP-1611885-A1 | Use of an inducing agent for the treatment of blood, viral and cellular disorders | Perrine, Susan P. (US) | 2006-01-04 | — | — | EP | claimed |
| US-5939456-A | METHOD OF STIMULATING THE EXPRESSION OF A GLOBIN PROTEIN, OR THE PROLIFERATION OR DEVELOPMENT OF ERYTHROID CELLS, MYELOID CELLS OR MEGAKARYOCYTIC CELLS FOR TREATING A DISORDER SELECTED FROM THE GROUP CONSISTING OF CYTOPENIA, AN ANEMIA AND | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 1999-08-17 | — | — | US | claimed |
| US-20240043430-A1 | CRYSTAL FORM OF CASEIN KINASE 1e INHIBITOR AND PREPARATION METHOD AND USE THEREOF | Hangzhou Healzen Therapeutics Co., Ltd. (CN) | 2024-02-08 | — | — | US | disclosed |
| CN-115477606-B | Method for rapidly converting ester into alkyne | 中国科学院兰州化学物理研究所 | 2024-01-26 | — | — | CN | disclosed |
| US-20230372311-A1 | COMPOSITIONS AND METHODS OF TREATING AGE-RELATED RETINAL DYSFUNCTION | UNIV CALIFORNIA (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230346788-A1 | METHODS FOR TREATING VIRAL DISORDERS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2023-11-02 | — | — | US | disclosed |
| EP-4269412-A1 | CRYSTAL FORM OF CASEIN KINASE 1E INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Hangzhou Healzen Therapeutics Co., Ltd. (CN) | 2023-11-01 | — | — | EP | disclosed |
| CN-110998800-B | Polishing liquid, polishing liquid set and polishing method | 株式会社力森诺科 | 2023-09-22 | — | — | CN | disclosed |
| CN-114656468-B | Crystal form of casein kinase 1 epsilon inhibitor, preparation method and application thereof | 杭州和正医药有限公司 | 2023-08-04 | — | — | CN | disclosed |
| US-11701363-B2 | Methods for treating viral disorders | TRUSTEES OF BOSTON UNIVERSITY (US) | 2023-07-18 | — | — | US | disclosed |
| US-6197743-B1 | CONCURRENT ADMINISTERING INDUCTION AGENT AND VIRICIDES | THE TRUSTEES OF BOSTON UNIVERSITY | 2001-03-06 | — | — | US | disclosed |
| EP-0969869-A2 | COMPOSITIONS COMPRISING AN INDUCING AGENT AND AN ANTI-VIRAL AGENT FOR THE TREATMENT OF BLOOD, VIRAL AND CELLULAR DISORDERS | Perrine, Susan P. (US) | 2000-01-12 | — | — | EP | disclosed |
| WO-1999040883-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FALLER DOUGLAS V (US) | 1999-08-19 | — | — | WO | disclosed |
| US-5939456-A | METHOD OF STIMULATING THE EXPRESSION OF A GLOBIN PROTEIN, OR THE PROLIFERATION OR DEVELOPMENT OF ERYTHROID CELLS, MYELOID CELLS OR MEGAKARYOCYTIC CELLS FOR TREATING A DISORDER SELECTED FROM THE GROUP CONSISTING OF CYTOPENIA, AN ANEMIA AND | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 1999-08-17 | — | — | US | disclosed |
| WO-1998004290-A2 | COMPOSITIONS COMPRISING AN INDUCING AGENT AND AN ANTI-VIRAL AGENT FOR THE TREATMENT OF BLOOD, VIRAL AND CELLULAR DISORDERS | PERRINE SUSAN P (US) | 1998-02-05 | — | — | WO | disclosed |
| US-5580702-A | COMPRISING A PHOTOSENSITIVE ACID-GENERATING COMPOUND AND A COPOLYMER OF P-HYDROXYSTYRENE AND AN ESTER OF P-CARBOXYMETHOXYSTYRENE; NONTOXIC; STEEP WALLS; HIGH SPEED; SEMICONDUCTORS | KABUSHIKI KAISHA TOSHIBA (JP) | 1996-12-03 | — | — | US | disclosed |
| US-5403695-A | Photolithography; high resolution; semiconductors | KABUSHIKI KAISHA TOSHIBA (JP) | 1995-04-04 | — | — | US | disclosed |
| US-4500713-A | TETRAHYDROISOQUINOLINE-3-CARBOXYLIC ACID DERIVATIVE AS ANTIHYPERTENSIVE AGENT | USV PHARMACEUTICAL CORPORATION (US) | 1985-02-19 | — | — | US | disclosed |
| US-3903134-A | Phenyl propionic acids and derivatives thereof | RORER INC WILLIAM H | 1975-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240043430-A1 | CRYSTAL FORM OF CASEIN KINASE 1e INHIBITOR AND PREPARATION METHOD AND USE THEREOF | CSNK1A1, CSNK1G1, CSNK1E | TSHR 3294/4885TP53 747/4885PDCD1 946/4885 |
| US-20230372311-A1 | COMPOSITIONS AND METHODS OF TREATING AGE-RELATED RETINAL DYSFUNCTION | RBP4, ALDH1A2, RBP1 | TSHR 2820/4885TP53 3695/4885PDCD1 4686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.